GlassScriptPhysician profile
Wen Wu
NPI 1861053985
$5,573.14
in general payments reported to CMS, 2019-2025
20 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $798 · 2023: $2,398 · 2024: $2,161 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,666.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,054.11 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $833.51 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $657.51 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $558.90 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $426.32 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $367.39 | 2023-2024 | |
| Gilead Sciences, INC. | $349.52 | 2022-2024 | Vemlidy |
| Almatica Pharma LLC | $255.08 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $254.50 | 2022-2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $254.23 | 2022-2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.81 | 2023-2024 | Jardiance |
| Abbvie INC. | $111.45 | 2023-2024 | Synthroid |
| Edwards Lifesciences Corporation | $96.36 | 2021 | |
| Amneal Pharmaceuticals LLC | $51.47 | 2023 | Lyvispah |
| Phathom Pharmaceuticals, INC. | $46.43 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.18 | 2022-2023 | |
| Abbott Laboratories | $23.32 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $17.51 | 2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.